keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast cancer therapy

keyword
https://www.readbyqxmd.com/read/28549010/a-clinical-feasibility-trial-for-identification-of-exceptional-responders-in-whom-breast-cancer-surgery-can-be-eliminated-following-neoadjuvant-systemic-therapy
#1
Henry M Kuerer, Gaiane M Rauch, Savitri Krishnamurthy, Beatriz E Adrada, Abigail S Caudle, Sarah M DeSnyder, Dalliah M Black, Lumarie Santiago, Brian P Hobbs, Anthony Lucci, Michael Gilcrease, Rosa F Hwang, Rosalind P Candelaria, Mariana Chavez-MacGregor, Benjamin D Smith, Elsa Arribas, Tanya Moseley, Mediget Teshome, Makesha V Miggins, Vicente Valero, Kelly K Hunt, Wei T Yang
OBJECTIVE: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted core biopsy (VACB) in assessing the presence of residual cancer in the breast after neoadjuvant systemic therapy (NST). SUMMARY BACKGROUND DATA: Pathologic complete response (pCR) rates after NST have improved dramatically, suggesting that surgery might be avoided in some patients. Safe avoidance of surgery would require accurate confirmation of no residual invasive/in situ carcinoma...
May 25, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28545563/additional-value-of-18-f-fdg-pet-ct-response-evaluation-in-axillary-nodes-during-neoadjuvant-therapy-for-triple-negative-and-her2-positive-breast-cancer
#2
Mette S van Ramshorst, Suzana C Teixeira, Bas B Koolen, Kenneth E Pengel, Kenneth G Gilhuijs, Jelle Wesseling, Sjoerd Rodenhuis, Renato A Valdés Olmos, Emiel J Rutgers, Wouter V Vogel, Gabe S Sonke, Marie-Jeanne T Vrancken Peeters
BACKGROUND: (18)F-FDG PET/CT can monitor metabolic activity in early breast cancer during neoadjuvant systemic therapy (NST), but it is unknown if the metabolic breast and axillary response differ. We evaluated the correlation between metabolic breast and axillary response at various time points during NST. Furthermore, we analysed if the combined metabolic response improves pathologic complete response (pCR) prediction compared to using the metabolic breast response alone. METHODS: (18)F-FDG PET/CT was performed at baseline (PET1), 2-3 weeks (PET2), and 6-8 weeks (PET3) of NST in patients with triple-negative (TN) and HER2-positive node-positive breast cancer...
May 25, 2017: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/28532642/optical-mammography-in-patients-with-breast-cancer-undergoing-neoadjuvant-chemotherapy-individual-clinical-response-index
#3
Pamela G Anderson, Sirishma Kalli, Angelo Sassaroli, Nishanth Krishnamurthy, Shital S Makim, Roger A Graham, Sergio Fantini
RATIONALE AND OBJECTIVES: We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxyhemoglobin ([HbO2]), deoxyhemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time points during chemotherapy. MATERIALS AND METHODS: Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on 10 patients before treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12, range: 7-18)...
May 19, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#4
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28526187/chemotherapy-may-eradicate-ductal-carcinoma-in-situ-dcis-but-not-the-associated-microcalcifications
#5
H Goldberg, J Zandbank, V Kent, M Leonov-Polak, A Livoff, A Chernihovsky, M Guindy, E Evron
INTRODUCTION: We studied the effect of neoadjuvant chemotherapy (NAC) ± trastuzumab on the ductal carcinoma in situ (DCIS) component in patients with locally advanced breast cancer who achieved pathological complete response (pCR). METHODS: The diagnostic biopsies of 92 consecutive breast cancer patients that were treated with neoadjuvant chemotherapy (NAC) ± trastuzumab were evaluated for the presence of DCIS. Upon completion of NAC, the surgical specimens were evaluated for complete eradication of both the invasive and non-invasive cancer in the breast...
May 4, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28524246/combined-pet-ct-and-axillary-lymph-node-marking-with-radioactive-iodine-seeds-mari-procedure-for-tailored-axillary-treatment-in-node-positive-breast-cancer-after-neoadjuvant-therapy
#6
B B Koolen, M Donker, M E Straver, M E M van der Noordaa, E J T Rutgers, R A Valdés Olmos, M J T F D Vrancken Peeters
BACKGROUND: The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND) is still the standard of care. Marking axillary lymph nodes with radioactive iodine seeds (MARI procedure) is accurate in restaging the axilla after NST (false-negative rate 7 per cent). Here, the potential of tailored axillary treatment, determined by combining the results of PET-CT before NST with those of the MARI procedure after NST, was analysed...
May 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#7
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28503722/fertility-preservation-with-ovarian-stimulation-and-time-to-treatment-in-women-with-stage-ii-iii-breast-cancer-receiving-neoadjuvant-therapy
#8
A Jo Chien, Julia Chambers, Fiona Mcauley, Tessa Kaplan, Joseph Letourneau, Jimmy Hwang, Mi-Ok Kim, Michelle E Melisko, Hope S Rugo, Laura J Esserman, Mitchell P Rosen
PURPOSE: To determine whether fertility preservation with ovarian stimulation (OS) results in treatment delay in breast cancer (BC) patients receiving neoadjuvant therapy (NAT). METHODS: This is a retrospective study of women screened for the prospective neoadjuvant ISPY2 trial at the University of California San Francisco. All patients were <43, had stage II-III BC, and received neoadjuvant therapy. Time to initiation of NAT was compared between women who underwent OS (STIM) and women who did not (control)...
May 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28495849/neoadjuvant-trials-in-er-breast-cancer-a%C3%A2-tool-for-acceleration-of-drug-development-and-discovery
#9
REVIEW
Angel L Guerrero-Zotano, Carlos L Arteaga
Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER(+)) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype...
May 11, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28487444/the-longitudinal-transcriptional-response-to-neoadjuvant-chemotherapy-with-and-without-bevacizumab-in-breast-cancer
#10
Laxmi Silwal-Pandit, Silje Nord, Hedda von der Lippe Gythfeldt, Elen K Møller, Thomas Fleischer, Einar Rødland, Marit Krohn, Elin Borgen, Øystein Garred, Tone Olsen, Phuong Vu, Helle Skjerven, Anne Fangberget, Marit M Holmen, Ellen Schlichting, Elisabeth Wille, Mette Nordberg Stokke, Hans Kristian Moen Vollan, Vessela N Kristensen, Anita Langerød, Steinar Lundgren, Erik A Wist, Bjørn Naume, Ole Christian Lingjerde, Anne-Lise Borresen-Dale, Olav Engebraaten
Chemotherapy induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab. <br />Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm.  Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks)...
May 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28484222/in-silico-evaluation-of-dna-damage-inducible-transcript-4-gene-ddit4-as-prognostic-biomarker-in-several-malignancies
#11
Joseph A Pinto, Christian Rolfo, Luis E Raez, Alexandra Prado, Jhajaira M Araujo, Leny Bravo, Williams Fajardo, Zaida D Morante, Alfredo Aguilar, Silvia P Neciosup, Luis A Mas, Denisse Bretel, Justin M Balko, Henry L Gomez
DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described that DDIT4 expression is an independent prognostic factor for tripe negative breast cancer resistant to neoadjuvant chemotherapy. We herein report that high DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overall survival) in several cancer types. We performed in silico analysis in online platforms, in pooled datasets from KM Plotter and meta-analysis of individual datasets from SurvExpress...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28480841/neoadjuvant-%C3%B0-hemotherapy-for-locally-advanced-breast-cancer
#12
Y Fomenko, V Sirota, I Omarova, N Kabildina, A Amanov
93 patients with LABC (T2N1-2M0, T3N0-2M0) at the age from 35 to 75 years were included in the trial. With 2 stage - 60 patients, with the third stage - 33 patients. All patients were randomized into 3 groups: The I control group (n=36) received 4 courses of neoadjuvant chemotherapy according to AC-protocol (doxorubicin 50 mg/m2, cyclophosphan-500 mg/m2 on day 1, repeated every three weeks) followed by radical mastectomy, 4 courses of adjuvant chemotherapy (АС), radiotherapy and hormone therapy if indicated...
March 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28479096/comparing-the-therapeutic-potential-of-thermosensitive-liposomes-and-hyperthermia-in-two-distinct-subtypes-of-breast-cancer
#13
Wouter J M Lokerse, Michiel Bolkestein, Simone U Dalm, Alexander M M Eggermont, Marion de Jong, Holger Grüll, Gerben A Koning
Local drug delivery of Doxorubicin (Dox) with thermosensitive liposomes (TSL) and hyperthermia (HT) has shown preclinically to achieve high local drug concentrations with good therapeutic efficacy. Currently, this is clinically studied for treatment of chest wall recurrence of breast cancer, however with various outcomes. This study examines the potency of neoadjuvant TSL HT combination therapy in two orthotopic mouse models of human breast cancer, MDA-MB-231 and T-47D, which morphologically correlate to mesenchymal and epithelial phenotypes, respectively...
May 4, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28478828/tidal-chemotherapy-in-premenopausal-patients-with-hormone-receptor-positive-breast-cancer
#14
Qing-Qing Luo, Jian-Bo Huang, Yu-Tuan Wu, Xin Li, Chun-Xia Zhao, He Wu, Wei Dai, Kai-Nan Wu, Ling-Quan Kong
Neoadjuvant chemotherapy remains an inseparable part of systemic therapy for hormone receptor positive (HR+) advanced breast cancer. However, efficacy of neoadjuvant chemotherapy in this subtype of patients is inferior to its hormone receptor negative counterpart. Several preclinical and clinical studies have suggested that it was growth rate rather than hormone receptor status that determined sensitivity to chemotherapy. In addition, estrogen was proved to recruit more HR+ breast cancer cells into actively dividing phase according to various studies...
May 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28477166/the-accuracy-of-18-f-fdg-pet-ct-in-predicting-the-pathological-response-to-neoadjuvant-chemotherapy-in-patients-with-breast-cancer-a-meta-analysis-and-systematic-review
#15
Fangfang Tian, Guohua Shen, Yunfu Deng, Wei Diao, Zhiyun Jia
OBJECTIVES: The aim of this meta-analysis was to evaluate the accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients. METHODS: PubMed, Embase, the Cochrane Library (Central), and the Web of Science (SCI-Expanded) were systematically searched to identify pertinent studies. The methodologic quality of the included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2...
May 5, 2017: European Radiology
https://www.readbyqxmd.com/read/28467142/monitoring-neoadjuvant-chemotherapy-for-breast-cancer-by-using-three-dimensional-subharmonic-aided-pressure-estimation-and-imaging-with-us-contrast-agents-preliminary-experience
#16
Kibo Nam, John R Eisenbrey, Maria Stanczak, Anush Sridharan, Adam C Berger, Tiffany Avery, Juan P Palazzo, Flemming Forsberg
Purpose To determine whether three-dimensional subharmonic aided pressure estimation (SHAPE) and subharmonic imaging can help predict the response of breast cancer to neoadjuvant chemotherapy. Materials and Methods In this HIPAA-compliant prospective study, 17 women (age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrasonography (US) immediately before therapy and at completion of 10%, 60%, and 100% of chemotherapy. All patients provided written informed consent...
May 3, 2017: Radiology
https://www.readbyqxmd.com/read/28466123/the-role-of-quantitative-estrogen-receptor-status-in-predicting-tumor-response-at-surgery-in-breast-cancer-patients-treated-with-neoadjuvant-chemotherapy
#17
REVIEW
Jacques Raphael, Sonal Gandhi, Nim Li, Fang-I Lu, Maureen Trudeau
PURPOSE: Estrogen receptor (ER) negative (-) breast cancer (BC) patients have better tumor response rates than ER-positive (+) patients after neoadjuvant chemotherapy (NCT). We conducted a retrospective review using the institutional database "Biomatrix" to assess the value of quantitative ER status in predicting tumor response at surgery and to identify potential predictors of survival outcomes. METHODS: Univariate followed by multivariable regression analyses were conducted to assess the association between quantitative ER and tumor response assessed as tumor size reduction and pathologic complete response (pCR)...
May 2, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28464832/the-e2f4-prognostic-signature-predicts-pathological-response-to-neoadjuvant-chemotherapy-in-breast-cancer-patients
#18
Kenneth M K Mark, Frederick S Varn, Matthew H Ung, Feng Qian, Chao Cheng
BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor's disease pathology. Developing genomic clinical assays that accurately categorize responders from non-responders can provide patients with the most effective therapy for their individual disease. METHODS: We applied our previously developed E2F4 genomic signature to predict neoadjuvant chemotherapy response in breast cancer...
May 2, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28463150/external-beam-radiation-therapy-or-brachytherapy-with-or-without-short-course-neoadjuvant-androgen-deprivation-therapy-results-of-a-multicenter-prospective-study-of-quality-of-life
#19
Hiram A Gay, Martin G Sanda, Jingxia Liu, Ningying Wu, Daniel A Hamstra, John T Wei, Rodney L Dunn, Eric A Klein, Howard M Sandler, Christopher S Saigal, Mark S Litwin, Deborah A Kuban, Larry Hembroff, Meredith M Regan, Peter Chang, Jeff M Michalski
PURPOSE: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer. METHODS AND MATERIALS: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28457577/proton-beam-radiotherapy-as-part-of-comprehensive-regional-nodal-irradiation-for-locally-advanced-breast-cancer
#20
Vivek Verma, Zaid Iftekaruddin, Nida Badar, William Hartsell, John Han-Chih Chang, Vinai Gondi, Mark Pankuch, Ming Gao, Stacey Schmidt, Darren Kaplan, Lisa McGee
PURPOSE: This study evaluates acute toxicity outcomes in breast cancer patients treated with adjuvant proton beam therapy (PBT). METHODS: From 2011 to 2016, 91 patients (93 cancers) were treated with adjuvant PBT targeting the intact breast/chest wall and comprehensive regional nodes including the axilla, supraclavicular fossa, and internal mammary lymph nodes. Toxicity was recorded weekly during treatment, one month following treatment, and then every 6months according to the Common Terminology Criteria for Adverse Events (CTCAE) v4...
May 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
keyword
keyword
74676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"